| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nemolizumab | CD-14152; CIM-331; M 5250; M 5250B | Approved | Chugai Pharmaceutical Co Ltd | Mitchga, Nemluvio | Japan | Dermatitis, Atopic; Pruritus | Maruho Co Ltd | 2022-03-28 | Dermatitis, Atopic; Prurigo; Prurigo Nodularis; Pruritus; Scleroderma, Systemic | Details |